{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:58:20Z","timestamp":1785491900502,"version":"3.56.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bullous diseases carry a great burden and are often linked to high healthcare costs. Patients with \u00adbullous diseases are more vulnerable to infections and organ damage due to an incompetent skin barrier.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the demographic, clinical and laboratory factors associated with prolonged hospital stay in patients with autoimmune bullous diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a cross-sectional study, with a follow-up cohort, including all dermatology consultations in a university hospital between 2017 and 2022 to identify patients with autoimmune bullous disease. Duration of stay and other variables were obtained from the patients\u2019 medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 83 patients were included in the study, of whom the majority \u00a0had bullous pemphigoid (n = 45; 54%). There was significant metabolic comorbidity with hypertension (n = 51; 61%), diabetes (n = 31; 37%) and dyslipidaemia (n = 31; 37%). Fifty-eight per cent of patients had a prolonged hospital stay (&amp;gt;10 days). Among the associated variables, mucosal involvement, eosinophilia, in-hospital antibiotics and the absence of dipetidyl peptidase-4 (DPP4) inhibitor use stood out.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most patients with bullous diseases have prolonged hospital stays. The evaluation of mucous membranes, blood count and a basic chemical panel can help identify patients at greater risk of prolonged hospital stays. In addition, the use of DPP4 inhibitors and their rapid discontinuation could affect this outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/skinhd\/vzag066","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:47:01Z","timestamp":1776858421000},"page":"528-538","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with prolonged hospital stay in patients with autoimmune bullous diseases treated at an in-patient dermatology service"],"prefix":"10.1093","volume":"6","author":[{"given":"Pedro Juan","family":"Saldarriaga-Mu\u00f1oz","sequence":"first","affiliation":[{"name":"Dermatology Service, Universidad CES , Medell\u00edn ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Rodelo-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Dermatology Service, Universidad CES , Medell\u00edn ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela","family":"Agudelo-Aguilar","sequence":"additional","affiliation":[{"name":"Dermatology Service, Universidad CES , Medell\u00edn ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Osorio-\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Plastic Surgery Service, Cl\u00ednica CES , Medell\u00edn ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Valencia-Montoya","sequence":"additional","affiliation":[{"name":"Universidad CES , Medell\u00edn ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Bedoya-Mej\u00eda","sequence":"additional","affiliation":[{"name":"Universidad CES , Medell\u00edn ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Chiquito-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Dermatology Service, Universidad CES , Medell\u00edn ,","place":["Colombia"]},{"name":"Dermatology Service, Cl\u00ednica CES , Medell\u00edn ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geovanna Andrea","family":"Ayala-Monroy","sequence":"additional","affiliation":[{"name":"Dermatology Service, Universidad CES , Medell\u00edn ,","place":["Colombia"]},{"name":"Dermatology Service, Cl\u00ednica CES , Medell\u00edn ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"2026073105092638500_vzag066-B1","first-page":"1339","article-title":"Bullous autoimmune dermatoses","volume":"16","author":"Hofmann","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026073105092638500_vzag066-B2","first-page":"927","article-title":"Autoimmune bullous skin diseases. Part 2: diagnosis and therapy","volume":"9","author":"Kneisel","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026073105092638500_vzag066-B3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjd.14821","article-title":"Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A","volume":"176","author":"Ren","year":"2017","journal-title":"Br J Dermatol"},{"key":"2026073105092638500_vzag066-B4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1001\/jamadermatol.2015.5240","article-title":"Costs of care for hospitalization for pemphigus in the United States","volume":"152","author":"Hsu","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2026073105092638500_vzag066-B5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/12034754221088562","article-title":"Bullous pemphigoid-associated mortality rate in a Canadian tertiary referral centre","volume":"26","author":"Cyr","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"2026073105092638500_vzag066-B6","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/jdv.18441","article-title":"Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study","volume":"36","author":"Bardazzi","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026073105092638500_vzag066-B7","doi-asserted-by":"crossref","DOI":"10.17533\/udea.iatreia.15985","article-title":"Enfermedades ampollosas autoinmunes del grupo de los p\u00e9nfigos","volume":"27","author":"Calle Isaza","year":"2014","journal-title":"Iatreia"},{"key":"2026073105092638500_vzag066-B8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.36104\/amc.2021.1844","article-title":"Factores asociados con estancia hospitalaria prolongada en una unidad geri\u00e1trica de agudos","volume":"46","author":"Ojeda M\u00e9ndez","year":"2020","journal-title":"Acta M\u00e9dica Colomb"},{"key":"2026073105092638500_vzag066-B9","first-page":"S206","article-title":"Causes of prolonged hospitalization among general internal medicine patients of a tertiary care center","volume":"97","author":"Ruangkriengsin","year":"2014","journal-title":"J Med Assoc Thai"},{"key":"2026073105092638500_vzag066-B10","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/MLR.0000000000001345","article-title":"Predicting patients at risk for prolonged hospital stays","volume":"58","author":"Doctoroff","year":"2020","journal-title":"Med Care"},{"key":"2026073105092638500_vzag066-B11","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-4632.2004.02501.x","article-title":"Pemphigus: analysis of 1209 cases","volume":"44","author":"Chams-Davatchi","year":"2005","journal-title":"Int J Dermatol"},{"key":"2026073105092638500_vzag066-B12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-4362.2000.00864.x","article-title":"Epidemiology of pemphigus in Sofia, Bulgaria. A 16-year retrospective study (1980\u20131995)","volume":"39","author":"Tsankov","year":"2000","journal-title":"Int J Dermatol"},{"key":"2026073105092638500_vzag066-B13","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-4632.2009.04345.x","article-title":"Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania","volume":"49","author":"Baican","year":"2010","journal-title":"Int J Dermatol"},{"key":"2026073105092638500_vzag066-B14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjd.19022","article-title":"Incidence, prevalence and mortality of bullous pemphigoid in England 1998\u20132017: a population-based cohort study","volume":"184","author":"Persson","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026073105092638500_vzag066-B15","doi-asserted-by":"crossref","first-page":"1159351","DOI":"10.3389\/fimmu.2023.1159351","article-title":"Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid","volume":"14","author":"Rosi-Schumacher","year":"2023","journal-title":"Front Immunol"},{"key":"2026073105092638500_vzag066-B16","doi-asserted-by":"crossref","DOI":"10.4081\/itjm.2024.1831","article-title":"Association of immunoglobulins and complement levels with pemphigus in patients at the Khartoum Dermatology and Venereal Disease Hospital, Sudan","volume":"18","author":"Elhag","year":"2024","journal-title":"Ital J Med"},{"key":"2026073105092638500_vzag066-B17","article-title":"Descripci\u00f3n sociodemogr\u00e1fica y cl\u00ednica de los pacientes con p\u00e9nfigo atendidos en el Hospital Universitario De La Samaritana de la ciudad de Bogot\u00e1 durante los a\u00f1os 2016 a 2020","author":"Camacho-P\u00e9rez","year":"","journal-title":"Reposistorio Universidad Nacional de Colombia"},{"key":"2026073105092638500_vzag066-B18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.29176\/2590843X.8","article-title":"Estudio retrospectivo cl\u00ednico-epidemiol\u00f3gico de los pacientes con p\u00e9nfigo y penfigoide ampolloso del Hospital Universitario San Vicente Fundaci\u00f3n","volume":"25","author":"Zuluaga","year":"2017","journal-title":"Rev Asoc Colomb Dermatol Cir Dermatol\u00f3gica"},{"key":"2026073105092638500_vzag066-B19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3390\/life12040595","article-title":"Comorbidities in patients with autoimmune bullous disorders: hospital-based registry study","volume":"12","author":"S\u00e1nchez-Garc\u00eda","year":"2022","journal-title":"Life"},{"key":"2026073105092638500_vzag066-B20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4274\/jtad.galenos.2020.68552","article-title":"Epidemiology and comorbidities of bullous pemphigoid: a retrospective study","volume":"14","author":"A\u015fk\u0131n","year":"2020","journal-title":"J Turk Acad Dermatol"},{"key":"2026073105092638500_vzag066-B21","doi-asserted-by":"crossref","first-page":"1196999","DOI":"10.3389\/fimmu.2023.1196999","article-title":"Comorbidity in bullous pemphigoid: up-date and clinical implications","volume":"14","author":"Huttelmaier","year":"2023","journal-title":"Front Immunol"},{"key":"2026073105092638500_vzag066-B22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/bjd\/ljae219","article-title":"Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids","volume":"191","author":"Kridin","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026073105092638500_vzag066-B23","doi-asserted-by":"crossref","first-page":"108546","DOI":"10.1016\/j.diabres.2020.108546","article-title":"Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: a population-based cohort study","volume":"171","author":"Wu","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"2026073105092638500_vzag066-B24","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study","volume":"138","author":"Varpuluoma","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2026073105092638500_vzag066-B25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3389\/fimmu.2018.00479","article-title":"Mucosal involvement in bullous pemphigoid is mostly associated with disease severity and to absence of anti-BP230 autoantibody","volume":"9","author":"Clap\u00e9","year":"2018","journal-title":"Front Immunol"},{"key":"2026073105092638500_vzag066-B26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.7241\/ourd.20224.8","article-title":"Mucosal involvement in bullous pemphigoid in Northeast Morocco","volume":"13","author":"Kassel","year":"2022","journal-title":"Our Dermatol Online"},{"key":"2026073105092638500_vzag066-B27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/jamadermatol.2018.5049","article-title":"Assessment of the prevalence of mucosal involvement in bullous pemphigoid","volume":"155","author":"Kridin","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2026073105092638500_vzag066-B28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.25259\/IJDVL_1527_2024","article-title":"Correlating pemphigus disease area index (PDAI) severity categories with oral disease severity score (ODSS) in oral mucosal pemphigus \u2013 a pilot study","volume":"92","author":"Sharma","year":"2025","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2026073105092638500_vzag066-B29","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.3389\/fimmu.2019.02571","article-title":"Assessing the correlation between disease severity indices and quality of life measurement tools in pemphigus","volume":"10","author":"Krain","year":"2019","journal-title":"Front Immunol"},{"key":"2026073105092638500_vzag066-B30","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ad.2022.05.021","article-title":"Association of peripheral blood and cutaneous eosinophils with bullous pemphigoid disease severity and treatment outcomes","volume":"113","author":"Garrido","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"2026073105092638500_vzag066-B31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.9734\/ajrdes\/2024\/v7i1104","article-title":"Eosinophilia in pemphigus: single center study in Morocco","volume":"7","author":"Alaoui","year":"2024","journal-title":"Asian J Res Dermatol Sci"},{"key":"2026073105092638500_vzag066-B32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijwd.2020.01.005","article-title":"Correlation of dermal and blood eosinophilia with bullous pemphigoid disease severity","volume":"6","author":"Farnaghi","year":"2020","journal-title":"Int J Womens Dermatol"},{"key":"2026073105092638500_vzag066-B33","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.16679","article-title":"Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation","volume":"179","author":"Kridin","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026073105092638500_vzag066-B34","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1346-8138.2006.00192.x","article-title":"Paraneoplastic pemphigus mimicking erosive mucosal lichen planus associated with primary hepatocellular carcinoma","volume":"33","author":"Yokokura","year":"2006","journal-title":"J Dermatol"},{"key":"2026073105092638500_vzag066-B35","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1346-8138.2011.01278.x","article-title":"Hepatotoxicity and liver enzyme alteration in patients with immunobullous diseases receiving immunosuppressive therapy: hepatotoxicity in immunobullous diseases","volume":"38","author":"Shahshahani","year":"2011","journal-title":"J Dermatol"},{"key":"2026073105092638500_vzag066-B36","first-page":"80","article-title":"Alterations in inflammation markers due to disease activation in autoimmune bullous diseases","volume":"31","author":"Sahin","year":"2023","journal-title":"Acta Dermatovenerol Croat"},{"key":"2026073105092638500_vzag066-B37","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.5826\/dpc.1501a4969","article-title":"Evaluation of the effects of systemic therapy on inflammatory markers and disease severity in patients with pemphigus","volume":"15","author":"G\u00fcner","year":"2025","journal-title":"Dermatol Pract Concept"},{"key":"2026073105092638500_vzag066-B38","first-page":"BC06","article-title":"Evaluation of anti-cyclic citrullinated peptide autoantibodies and C-reactive protein in common autoimmune skin diseases with and without arthritis","volume":"11","author":"Kumari","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"2026073105092638500_vzag066-B39","first-page":"312","article-title":"Serologic biomarkers in pemphigus monitoring: C-reactive protein, macrophage migration inhibitory factor, and prolactin levels versus autoantibody assays","volume":"22","author":"Mortazavi","year":"2023","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"2026073105092638500_vzag066-B40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.25259\/IJDVL_705_2021","article-title":"Survival and prognostic factors in bullous pemphigoid: a retrospective cohort study","volume":"89","author":"Papara","year":"2022","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2026073105092638500_vzag066-B41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12941-020-00388-6","article-title":"Features and associated factors of bacterial skin infections in hospitalized patients with pemphigus: a single-center retrospective study","volume":"19","author":"Li","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2026073105092638500_vzag066-B42","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.3390\/jcm11102856","article-title":"A review of the immunologic pathways involved in bullous pemphigoid and novel therapeutic targets","volume":"11","author":"Afarideh","year":"2022","journal-title":"J Clin Med"},{"key":"2026073105092638500_vzag066-B43","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jaad.2025.01.086","article-title":"Bullous pemphigoid: a practical approach to diagnosis and management in the modern era","volume":"92","author":"Powers","year":"2025","journal-title":"J Am Acad Dermatol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/528\/68499836\/vzag066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/528\/68499836\/vzag066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:09:41Z","timestamp":1785488981000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/4\/528\/8704607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,6,9]]},"published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag066","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,9]]}}}